EPIDERMOLYSIS BULLOSA (EB)
Clinical trials for EPIDERMOLYSIS BULLOSA (EB) explained in plain language.
Never miss a new study
Get alerted when new EPIDERMOLYSIS BULLOSA (EB) trials appear
Sign up with your email to follow new studies for EPIDERMOLYSIS BULLOSA (EB), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene therapy skin graft aims to heal wounds in 'Butterfly Children'
Disease control Not yet recruitingThis trial evaluates a gene therapy skin graft called prademagene zamikeracel (pz-cel) for treating wounds in people with recessive dystrophic epidermolysis bullosa (RDEB), a severe genetic condition that causes fragile skin and chronic wounds. The study includes three parts: one…
Matched conditions: EPIDERMOLYSIS BULLOSA (EB)
Phase: PHASE4 • Sponsor: Abeona Therapeutics, Inc • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Oxygen chamber therapy put to the test for dozens of diseases
Disease control Not yet recruitingThis study will test hyperbaric oxygen therapy (HBOT) — breathing pure oxygen in a pressurized chamber — for over 30 conditions, including long COVID, Crohn's disease, frostbite, and multiple sclerosis. Researchers will track 100 patients to see if HBOT improves their quality of …
Matched conditions: EPIDERMOLYSIS BULLOSA (EB)
Phase: PHASE4 • Sponsor: Jay C. Buckey Jr. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New hope for blistering skin diseases: drug targets antibodies to heal wounds
Disease control Not yet recruitingThis early-phase study tests whether the drug efgartigimod (VYVGART) can lower harmful collagen VII antibodies and improve wound healing in people with two rare blistering skin conditions: recessive dystrophic epidermolysis bullosa (RDEB) and epidermolysis bullosa acquisita (EBA)…
Matched conditions: EPIDERMOLYSIS BULLOSA (EB)
Phase: PHASE1, PHASE2 • Sponsor: M. Peter Marinkovich • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New cream aims to soothe butterfly skin in Late-Stage trial
Symptom relief Not yet recruitingThis Phase 3 study tests the safety of SD-101 cream (6% allantoin) in 80 people with epidermolysis bullosa, a condition that causes fragile, blistering skin. Participants must have completed a prior study (SD-007). The main goal is to track any side effects over time.
Matched conditions: EPIDERMOLYSIS BULLOSA (EB)
Phase: PHASE3 • Sponsor: Paradigm Therapeutics • Aim: Symptom relief
Last updated Jun 27, 2026 11:03 UTC